THE BANK OF NEW YORK MELLON
101 Barclay Street
New York, New York 10286
December 4, 2017
Securities & Exchange Commission
450 Fifth Street, NW
Washington, DC 20549
Attn.: Document Control
| RE: | American Depositary Shares representing ordinary shares of |
| Prima BioMed Ltd | |
| (Form F-6 File No 333-180538) | |
| *************************** |
Ladies and Gentlemen:
Pursuant to Rule 424(b)(3) under the Securities Act of 1933, as amended, on behalf of BNY Mellon, as Depositary for securities against which American Depositary Receipts are to be issued, we attach a copy of the new prospectus (“Prospectus”) reflecting a change to the form of receipt for Prima BioMed Ltd.
Pursuant to Section III B of the General Instructions to the Form F-6 Registration Statement, the Prospectus consists of the form of American Depositary Receipts that evidence the American Depositary Shares with the revised name for Prima BioMed Ltd, which has been changed to Immutep Limited.
As required by Rule 424(e), the upper right hand corner of the Prospectus cover page has a reference to Rule 424(b)(3) and to the file number of the registration statement to which the Prospectus relates.
The Prospectus has been revised to reflect the new name as follows:
“Immutep Limited”
Please contact me with any questions or comments at 212 815-4888.
Vanessa Salazar
Vice President
The Bank of New York Mellon - ADR Division
Encl.
CC: Office of International Corporate Finance
